Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Vaxart Inc (Vaxart) is a clinical-stage biotechnology company which focuses on developing oral recombinant vaccines. The company's main activities involve the research and development of vaccine candidates using its proprietary Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform. Vaxart is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer and dysplasia caused by human papilloma virus (HPV). Vaxart is headquartered in San Francisco, California, the US.Vaxart Inc Key Recent Developments
- May 29, 2025: Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders
- May 13, 2025: Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
- May 13, 2025: Vaxart Appoints Jeroen Grasman as Chief Financial Officer
- Mar 20, 2025: Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sinovac Biotech Ltd
- Sanofi
- Johnson & Johnson Innovative Medicine
- CSL Ltd
- Anhui Zhifei Long Kema Biological Pharmaceutical Co Ltd
- Novartis AG
- Genexine Inc
- Inovio Pharmaceuticals Inc
- HilleVax Inc
- Medicago Inc
- F. Hoffmann-La Roche Ltd
- Novavax Inc
- Pfizer Inc
- Merck & Co Inc
- Moderna Inc
- Emergent BioSolutions Inc
- Selva Therapeutics Inc
- GSK plc
- Ayala Pharmaceuticals Inc.